Latest Industry Insights

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

At ASMS 2023, Technology Networks spoke with Jim Yano, senior director of product management at Thermo Fisher Scientific, to learn more about the company's novel instrument launches and how they could be applied to personalized medicine.

Unlocking more information from our proteome could deepen our understanding of disease, improve detection and influence drug selection. To find out more about single-molecule proteomics, we spoke to Parag Mallick, co-founder of Nautilus Biotech.

At the 71st Annual Society for Mass Spectrometry (ASMS) meeting, Technology Networks had the pleasure of speaking with Rohan Thakur, president of Life Sciences Mass Spectrometry at Bruker Daltonics. We discussed the new product launches from Bruker and focused specifically on the applications of the company’s newest mass spectrometer, the timsTOF Ultra, for immunopeptidomics.

The 10-year anniversary of SWATH DIA signifies a period of immense growth that is only expected to continue to evolve, influencing a wide range of fields. This article explores key milestones for SWATH DIA since its development.

To find out more about how proteomics is providing new insights into cancer dynamics and resistance mechanisms, we spoke to Dr. Ofer Sharon, CEO of OncoHost, a precision diagnostics company.

Technology Networks spoke with Anjali Pradhan, senior vice president of product management at Mission Bio, to discuss a new application for DNA methylation analysis, and its potential in uncovering new biological insights and biomarkers that may guide the future of cancer research.

This article will cover innovations in structural proteomics, a new way to identify drug targets across the proteome, a new method to dissect drug–protein interactions and the future of structure-based drug design.

Technology Networks spoke to Katherine Tran from SCIEX about the latest advances in data-independent acquisition mass spectrometry and how it can be used to further our understanding of the proteome in health and disease.

To find out more about the importance of improving biomarker discovery and how next-generation mass spectrometry-based systems can help to fill the current gap in biomarker technologies, Technology Networks spoke with Dr. Mo Jain.